Human Normal Immunoglobulin clinical trials

Explore recruiting human normal immunoglobulin clinical trials.

Recruiting human normal immunoglobulin studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Human Normal Immunoglobulin trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases

Italy, Slovakia, Hungary, Poland, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 years) with Non-cystic Fibrosis Bronchiectasis

Spain, Belgium, Germany, Greece, Denmark, Netherlands +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy.

Slovenia, Estonia, Greece, Portugal, Slovakia, Czechia +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Open-label, Single Arm, Prospective, Multicenter Study to Assess Efficacy and Safety of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Adult Patients with Chronic Immune Thrombocytopenia (ITP)

Germany, Spain, Czechia, Italy, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Czechia, Bulgaria, Netherlands, Hungary, Sweden, Slovakia +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Human Normal Immunoglobulin trials by city

Human Normal Immunoglobulin in Toronto Human Normal Immunoglobulin in Vancouver Human Normal Immunoglobulin in Montreal Human Normal Immunoglobulin in Calgary Human Normal Immunoglobulin in Edmonton Human Normal Immunoglobulin in Ottawa Human Normal Immunoglobulin in Winnipeg Human Normal Immunoglobulin in Quebec City Human Normal Immunoglobulin in Hamilton Human Normal Immunoglobulin in Kitchener Human Normal Immunoglobulin in London Human Normal Immunoglobulin in Halifax Human Normal Immunoglobulin in New York Human Normal Immunoglobulin in Los Angeles Human Normal Immunoglobulin in Chicago Human Normal Immunoglobulin in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease